检索结果-南通市图书馆

The History of Controlling and Treating Infectious Diseases in Ancient China

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2024年第1期44卷 64-70页

作者： Cui-ling LIU Tao ZHOU Liang-bin CHENG David fisher Khrystyna PRONYUK Erkin MUSABAEV Yi-ping DANG Lei ZHAO Department of Infectious Diseases Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Department of Gastroenterology and Hepatology Huanggang Hospital of Traditional Chinese MedicineHubei University of Chinese MedicineHuanggang 438000China Clinical College of Traditional Chinese Medicine Hubei University of Chinese MedicineWuhan 430065China Department of Liver Diseases Hubei Hospital of Traditional Chinese MedicineWuhan 430061China Department of Medical Biosciences Faculty of Natural SciencesUniversity of the Western CapeBellvilleCape Town 7535South Africa Department of Infectious Diseases Bogomolets National Medical UniversityKyiv 02132Ukraine The Research Institute of Virology Ministry of HealthTashkent 100122Uzbekistan Department of Vascular Surgery Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China

Infectious diseases are the common enemies of *** the course of historical development,they persistently threaten human health and *** today,despite the developments in medical science,we cannot escape the fear and suffering caused by infectious *** in ancient or modern times,the source of infection,route of transmission,and a susceptible population are the three key conditions for the prevalence and spread of infectious *** factors closely related to these three conditions can affect the prevalence of infectious *** is one of the cradles of world *** ancient people accumulated a great deal of experience and lessons in the long struggle against infectious *** the face of the current threat posed by widespread infectious disease,it is imperative to review and summarize ancient Chinese ideas and health policies on epidemic prevention and control to inspire contemporary efforts in the prevention and control of infectious *** combination of prevention-oriented epidemic prevention ideology and traditional medicine provides valuable insights,especially for impoverished and medically underserved regions.

关键词： infectious diseases Chinese medicine public health historical review

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open- label, controlled trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2024年第1期9卷 82-89页

作者： Yunyun Xiong Bruce C V Campbell Marc fisher Lee H Schwamm Mark Parsons Hao Li Yuesong Pan Xia Meng Xingquan Zhao Yongjun Wang Neurology Beijing Tiantan HospitalBeijingChina China National Clinical Research Center for Neurological Diseases BeijingChina Department of Medicine and Neurology The University of MelbourneMelbourneVictoriaAustralia Neurology Beth Israel Deaconess Medical CenterBostonMassachusettsUSA Department of Neurology and Comprehensive Stroke Center Massachusetts General HospitalBostonMassachusettsUSA Department of Neurology University of New South Wales South Western Sydney Clinical SchoolLiverpoolNew South WalesAustralia

Background and purpose Recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)was not inferior to alteplase for ischaemic stroke within *** study aimed to investigate the efficacy and safety of rhTNK-tPA in patients who had an ischaemic stroke due to large vessel occlusion(LVO)of anterior circulation beyond *** and design Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-III(TRACE III)is a multicentre,prospective,randomised,open-label,blind endpoint,controlled clinical *** who had an ischaemic stroke due to anterior circulation LVO(internal carotid artery,middle cerebral artery M1 and M2 segments)within 4.5–24hours from last known well(including wake-up stroke and no witness stroke)and with salvageable tissue(ischaemic core volume6s at 24 hours and NIHSS score change from baseline at *** outcomes are symptomatic intracerebral haemorrhage within 36 hours and mortality at 90 *** TRACE III will provide evidence for the efficacy and safety of rhTNK-tPA in patients who had an ischaemic strokes due to anterior circulation LVO beyond *** registration number NCT05141305.

关键词： Therapy random Rational

MYC蛋白高表达弥漫大B细胞淋巴瘤45例分子特征分析

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

临床与实验病理学杂志 2024年第1期40卷 60-65页

作者：刘念马东慎顾滢骆丹范美婷王玉波向臣希刘慧徐州医科大学病理学教研室徐州221000 徐州医科大学附属医院病理科徐州221000

目的探讨MYC蛋白高表达弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的分子特征。方法收集45例DLBCL临床资料。采用免疫组化EnVision法将患者分为MYC蛋白高表达/低表达组。所有样本均行DNA靶向测序,并使用LymphGen在线工具... 详细信息

目的探讨MYC蛋白高表达弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的分子特征。方法收集45例DLBCL临床资料。采用免疫组化EnVision法将患者分为MYC蛋白高表达/低表达组。所有样本均行DNA靶向测序,并使用LymphGen在线工具进行分子分型。运用Lymph2Cx法对细胞起源进行测定。采用χ^(2)检验和fisher精确检验分析MYC蛋白高表达与临床病理参数的相关性。绘制生存曲线并使用Cox单因素、多因素回归分析生存相关因素。结果DLBCL病例分为MYC蛋白高表达组(n=17)和低表达组(n=28),与MYC蛋白低表达组相比,MYC蛋白高表达组PIM1、MYD88、CD79B、CD58和PRDM1的突变率较高(76.5%vs 28.6%,70.6%vs 32.1%,58.8%vs 28.6%,29.4%vs 3.6%,29.4%vs 3.6%,P均<0.05);分子亚型以MCD亚型多见(58.8%vs 10.7%,P=0.001);COO亚型GCB少见(17.6%vs 50.0%,P=0.030)。MYC蛋白高表达患者的总生存期显著缩短(P<0.05);Cox多因素分析显示,年龄是DLBCL的独立预后因素(P<0.05)。结论MYC蛋白高表达多为MCD型和ABC型,常见PIM1、MYD88、CD79B、CD58和PRDM1突变。MYC蛋白高表达的患者预后较差。

关键词：弥漫大B细胞淋巴瘤 MYC 分子分型细胞起源免疫组织化学

维普期刊数据库

在线全文

学校读者我要写书评

暂无评论

华尔街之舞

作者： (美)肯·费雪(Ken fisher)

来源：南通市图书馆图书评论

学校读者我要写书评

暂无评论

盔甲骑士

Polycystic Ovarian Syndrome (PCOS): Exploring Its Impact on Obstetrical Outcomes

作者： ((美.fisher) Robert)费希尔

来源：南通市图书馆图书评论

学校读者我要写书评

暂无评论

Open Journal of Obstetrics and Gynecology 2024年第8期14卷 1111-1123页

作者： Ranjitha Vasa Gayatri Venkataraman Kelly Gorman Rythika Francis Elise Zwicklbauer Julia fisher Polina Safovich Mudar Dalloul Ozgul Muneyyirci-Delale Department of Obstetrics and Gynecology SUNY Downstate Health Science University Brooklyn United States of America Department of Obstetrics and Gynecology Kings County Hospital Center NYC Health and Hospitals Brooklyn United States of America

Polycystic ovarian syndrome (PCOS) disrupts ovulation leading to both infertility and miscarriage;yet, its impact on obstetrical outcomes remains largely uncertain due to conflicting findings. We analyzed data from the CDC Pregnancy Risk Assessment of Monitoring System, specifically Standard Core and Phase 8 responses, with 9549 respondents across the United States through SPSS 28 software in this cross-sectional study. Two variables assessed PCOS status in respondents: history of PCOS and PCOS during pregnancy. With a history of PCOS, there were significantly increased odds of diabetic (OR 1.665, p < 0.001), hypertensive disorders (OR 1.589, p < 0.001) during pregnancy, neonatal mortality (OR 1.550, p < 0.001), cesarean section (C/S) (OR 1.489, p < 0.001), and preterm prelabor rupture of membranes (PPROM) (OR 2.081, p < 0.001). With PCOS diagnosed during pregnancy, there were significantly greater odds of diabetes (OR 3.278, p < 0.001), hypertensive disorders (OR 2.935, p < 0.001) during pregnancy, and significantly decreased risk for small for gestational age (2 standard deviations) (OR 0.337, p = 0.024). PCOS is a significant risk factor that contributes to maternal morbidity. Our results support the hypothesis that PCOS’ impact extends well into a woman’s obstetrical journey, with varying degrees of associated adverse maternal and fetal risks. Preliminary pathophysiologic explanations associated with PCOS gestational diabetes include pre-existing insulin resistance. Meanwhile, altered placentation and endovascular changes associated with PCOS secondary to a baseline deranged metabolic environment predispose patients to developing hypertensive disorders, PPROM, and preterm delivery. Associations between neonatal mortality and C/S can be attributed to elevated maternal body mass index. The pathophysiologic link between PCOS and the above obstetrical outcomes still remains unknown, necessitating further investigation;however, this study identifies the outcomes that

关键词： PCOS Polycystic Ovarian Syndrome Obstetrics Reproduction Pregnancy

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

创业融资，从一个好故事开始

THE STATUS OF ESTROGEN RECEPTOR OF BREAST CANCER CELLS

作者： (美)比尔·费舍尔(Bill fisher)

来源：南通市图书馆图书评论

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 1985年第8期98卷 607-612页

作者：郑树 Bernard fisher Nurten Gunduz Department of Surgical Oncology Second Affiliated Hospital Zhejiang Medical University Hangzhou University of Pittsburge U.S.A.

On the basis of the location and intensity of fluoresceinate estradiol or 17-fluoresceinate-estrone binding with breast cancer cells, the estrogen receptor (ER) status of breast cancer cells could be classified into Types A, B, C, D and E. Type A was entire cell with marked fluorescence, Type B was nucleus with marked fluorescence but not cytoplasm, Type C was cytoplasm with marked fluorescence but nucleus, Type D was only fluorescence concentrated in the nucleolus, and Type E was very faint fluorescence of the entire cell. Types A, B and C were categorized as positive, Types D and E were negative. The evaluation of twenty human breast cancer cells binding with fluoresceinate-estradiol ligand by computer image processing technique showed that each of the five types of cells could be identified. Instant and contiguous observation after dropping 17-fluoresceinate-estrone revealed that these five types of cells existed ordinarily. The classification of breast cancer cells binding with fluorescence indicated the distribution of ER within a cell, which makes it possible for further study on the biological characteristics of ER with morphological patterns.

关键词：

Brain cytoprotection of ischemic stroke in the era of effective reperfusion

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Science Bulletin 2022年第23期67卷 2372-2375页

作者： Di Wu Ming Li Marc fisher Xunming Ji Department of Neurology and China-America Institute of Neuroscience Xuanwu HospitalCapital Medical UniversityBeijing 100053China Bejing Institute of Brain Disorders Capital Medical UniversityBeijing 100053China Departmentof Neurology Beth Israel Deaconess Medical CenterHarvard Medical SchoolBoston 02215USA

Acute ischemic stroke (AIS) treatment has been advanced by the development of recanalization therapies, especially endovascular thrombectomy. Thrombectomy has led to a better prognosis at 90 d not only in stroke patients because of large-vessel occlusion in the proximal anterior cerebral circulation, but also in those due to basilar-artery occlusion [1]. Thus, the number of eligible patients for revascularization will continue to increase.

关键词：缺血性卒中 occlusion Acute

维普期刊数据库